Abstract
AbstractAvibactam is a non‐β‐lactam based second generation β‐lactamase inhibitor containing diazabicyclooctane (DBO) ring as the β‐lactam mimic. We substituted C2 position of DBO scaffold by a number of amidine derivatives to form water soluble final compounds A1‐A14. The synthesized compounds were evaluated for their antibacterial and synergistic activity in combination with an antibiotic in vitro. The compounds, were tested against ten bacterial strains alone and in combination with existing antibiotic, meropenem. All compounds didn't show antibacterial activity when alone (MIC,>128 μM), however exhibited moderate to good synergistic activity in the presence of meropenem by lowering its MIC values. Compound A7 proved the most potent among other counterparts against all bacterial species with MIC from <0.29 μM to 2.34 μM, and showed comparable or improved activity to avibactam against eight bacterial strains. Compound A7 may prove a lead for next level in vivo and clinical studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
